Evidence map›Paper›PMID 32695997›Full record

ArticleCritical care explorations2020

International Survey of Thrombolytic Use for Treatment of Cardiac Arrest Due to Massive Pulmonary Embolism.

Megan A Rech, Michelle Horng, Jenna M Holzhausen, Megan A Van Berkel, Sarah S Sokol, Sarah Peppard, Drayton A Hammond

Open access · goldAbstract read
In one paragraph

Article in Critical care explorations, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 1 country.

Megan A RechDepartment of Pharmacy, Loyola University Medical Center, Maywood, IL.
Michelle HorngDepartment of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX.
Jenna M HolzhausenDepartment of Pharmacy, Beaumont Hospital, Royal Oak, MI.
Megan A Van BerkelDepartment of Pharmacy, Erlanger Health System, Chattanooga, TN.
Sarah S SokolDepartment of Pharmacy, The University of Chicago Medicine, Chicago, IL.
Sarah PeppardDepartment of Pharmacy, Froedtert & the Medical College of Wisconsin, Milwaukee, WI.
Drayton A HammondDepartment of Pharmacy, Rush University Medical Center, Chicago, IL.
Loyola University Medical Center · USBeaumont Hospital, Royal Oak · USConcordia University Wisconsin · USErlanger Health System · USThe University of Texas MD Anderson Cancer Center · USUniversity of Chicago · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThis survey sought to characterize the national prescribing patterns and barriers to the use of thrombolytic agents in the treatment of pulmonary embolism, with a specific focus on treatment during actual or imminent cardiac arrest.

designA 19-question international, cross-sectional survey on thrombolytic use in pulmonary embolism was developed, validated, and administered. A multivariable logistic regression was conducted to determine factors predictive of utilization of thrombolytics in the setting of cardiac arrest secondary to pulmonary embolism.

settingInternational survey study. SUBJECTS: Physicians, pharmacists, nurses, and other healthcare professionals who were members of the Society of Critical Care Medicine.

interventionsNone. MEASUREMENTS AND MAIN

resultsThrombolytic users were compared with nonusers. Respondents (

conclusionsMost survey respondents used thrombolytics in the setting of cardiac arrest secondary to known or suspected pulmonary embolism. This survey study adds important data to the literature surrounding thrombolytics for pulmonary embolism as it describes thrombolytic user characteristic, barriers to use, and common prescribing practices internationally.

Indexed as

cardiac arrestmassive pulmonary embolismpulmonary embolismthrombolytic

Identifiers

PMID32695997
PMCPMC7314323
OpenAlexW3034512529

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.